Orschiedt J, Jacyshyn-Owen E, Kahn M, Jansen S, Joschko N, Eberl M, Schneeweiss S, Friedrich B, Ziemssen T. The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany. Biomed Pharmacother. 2023 Feb;158:114129.

Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, et al. Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm 2023;10(1).

Ziemssen T, Groth M, Ettle B, Bopp T. Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab. Vaccines (Basel). 2022 Dec 16;10(12):2167.

Ness N-H, Schriefer D, Haase R, Ziemssen T. The Multiple Sclerosis Health Resource Utilization Survey. Fortschr Neurol Psychiatr 2022;90(1-2):42-48.

Schriefer D, Haase R, Ness N-H, Ziemssen T. Cost of illness in multiple sclerosis by disease characteristics–A review of reviews. Expert Rev Pharmacoecon Outcomes Res 2022;22(2):177-195.

Doose A, Hellerhoff I, Tam FI, King JA, Seidel M, Geisler D, et al. Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. Psychoneuroendocrinology 2022;135.

Ziemssen T, Haase R. Digital Innovation in Multiple Sclerosis Management. Brain Sci 2022;12(1).

Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis 2022;13.